A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
University of Colorado, Denver
GlaxoSmithKline
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
ModeX Therapeutics, An OPKO Health Company
Stanford University
Mayo Clinic
Universitat Jaume I
Stanford University
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
UTC Therapeutics Inc.
Jules Bordet Institute
Assiut University
Dublin City University
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
Institut de Cancérologie de Lorraine
MacroGenics
Stryker Orthopaedics
Imperial College London
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Imperial College London
Instituto do Cancer do Estado de São Paulo
University of Iowa
Ohio State University Comprehensive Cancer Center
Johns Hopkins Bloomberg School of Public Health
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Johns Hopkins Bloomberg School of Public Health
National Cancer Institute (NCI)
UNICANCER
Alliance for Clinical Trials in Oncology
University of Washington
Memorial Sloan Kettering Cancer Center
Institut Mutualiste Montsouris
Memorial Sloan Kettering Cancer Center